Patent SG-11201909160W-A (SG)
Title: Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
Inventor: ECKELMAN BRENDAN P
IPC: C07K16/46
Filed: 2018-04-11
Abstract: FIGUncleaved/Inactivated Cleaved/Activated Component #1 TAA-binding TAA-binding domain #1 domain #1 Linkers:protease t cleavage sites Anti-CD3-dsFv: Constrained —No Bindin TAA-binding TAR-binding domain #2 domain n v4f Component #2 Exposed Anti-CD3-dshi Region TAA-binding TAA-binding domain #1 domain #1 Component #1 Component #2 IgG-Fc Fc - tits (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WI P0 I Iiiimmonimmonolomomummllonomovois (10) International Publication Number WO 2018/191438 Al PCT (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) (21) International Application Number: PCT/US2018/027195 (22) International Filing Date: 11 April 2018 (11.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/484,217 11 April 2017 (11.04.2017) US (71) Applicant: INHIBRX, INC. [US/US]; 11099 North Torrey Pines Road, Suite 280, La Jolla, California 92037 (US). (72) Inventors: ECKELMAN, Brendan P.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). KAPLAN, Michael D.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). WILLIS, Katelyn M.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). DEVERAUX, Quinn; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cal- ifornia 92037 (US). TIMMER, John C.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). (74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME TM-binding TAR-binding domain #2 domain #2 (57) : The disclosure relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications. [Continued on next page] WO 2018/191438 Al IMEDIMOM0101011M1E130HHOMBEHMEMNIE UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))